Tecan and Invitrogen announce agreement to jointly develop and promote applications of Invitrogen research kits on Tecan instruments
Tecan and Invitrogen have announced an agreement to promote the use of Invitrogen's research kits on Tecan's instruments for a wide variety of key biological science and drug discovery applications.
Under the non-exclusive open collaboration agreement, Tecan and Invitrogen will collaborate in the development of applications that combine the use of Invitrogen's products with Tecan's Freedom Evo series of automated platforms, multimode detection devices and microarray systems for a range of life science applications, including nucleic acid sample preparation, microarray applications and cell-based assays.
Invitrogen and Tecan will work together to develop solutions for each application.
Both companies will promote the solutions arising from the collaboration.
Invitrogen provides solutions across the continuum of drug discovery, development and production, including gene expression analysis and high-throughput screening.
These products allow scientists to perform experiments faster, easier and more reliably.
Tecan is a provider of modular platforms for liquid handling and robotics.
The Freedom Evo series of automated platforms offers state-of-the-art liquid handling capabilities as well as compliance with the very latest regulatory requirements. Jan Timmers, executive vice president marketing at Tecan, remarked: "We are extremely pleased to join forces with a leading manufacturer of products and services for life science research.
"In collaboration with Invitrogen, we will develop a whole series of solutions allowing the implementation of important technologies on Tecan's automated platforms". Achim Wehren, product group manager biopharma, added: "The combination of Tecan's flexible modular platforms with the powerful genomic and drug discovery solutions from Invitrogen will bring significant benefits to customers worldwide in terms of reliability, reproducibility, process safety, and throughput".
Ben Bulkley, senior vice president, global commercial operations with Invitrogen, commented: "Through our collaboration with Tecan, we are able to further our role as the pre-eminent partner in drug discovery research.
"By combining our comprehensive portfolio of research technologies with a flexible automated platform, we can deliver a more effective system for drug discovery, development and production".
He added: "This alliance is the latest step to deliver a complete solution for drug discovery and accelerate research across the industry."
